Obesity: Drugs
(asked on 1st September 2025) - View Source
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, whether he has considered including lipedema as a relevant condition for NHS prescription of (a) Mounjaro injections and (b) other weight loss treatments.
Semaglutide, brand name Wegovy, tirzepatide, brand name Mounjaro, and liraglutide, brand name Saxenda, are approved for the management of obesity. They are recommended as cost-effective for use on the National Health Service for people who have a body mass index (BMI) over a certain threshold, and one or more weight-related comorbidities.
The marketing authorisations for tirzepatide and other weight loss medicines do not include an exhaustive list of qualifying comorbidities, and it is for the prescriber to apply their clinical judgement in determining whether a patient meets the eligibility criteria.
The exact causes of lipoedema are not clear, and the NHS.UK website states that it’s not caused by being overweight, and that it is a separate condition to obesity.
The NHS is currently rolling out tirzepatide in primary care, using a phased approach based on clinical need. Approximately 220,000 individuals are expected to be eligible over the next three years. NHS England worked with clinical experts, NHS integrated care boards, patient and public representatives, healthcare professionals, charities, and royal colleges on its prioritisation approach, which it set out in its interim commissioning guidance, at the following link:
At the current time, patients will be eligible for treatment in primary care if they have a BMI of at least forty, and four or more out of five ‘qualifying' conditions. The qualifying conditions for tirzepatide treatment are cardiovascular disease, hypertension, dyslipidaemia, obstructive sleep apnoea, and type 2 diabetes mellitus.